Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis

Mark E. Williams*, Michael Weinblatt, Robert M. Rosa, Victoria L. Griffin, M. Barry Goldlust, Shaw F. Shang, Lester I. Harrison, Robert S. Brown

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


A 1500 mg dose of salsalate (SSA) was given to five patients undergoing chronic hemodialysis on an interdialytic day and again before dialysis. Compared with control subjects, patients undergoing dialysis had a lower peak plasma SSA level (17 ± 3 vs. 45 ± 2 μg/ml; P < 0.01) that occurred slightly later. In contrast, plasma salicylic acid (SA), the active SSA metabolite, had a similar but later peak level that remained substantially higher. Therefore, the AUC for SA was increased by 50% and the SA t½was prolonged in the patients receiving dialysis (8.1 ± 0.7 vs. 3.8 ± 0.2 hours; P < 0.01). During a single treatment, dialysis clearance reduced plasma SA levels, removed 18% of total body SA, and returned the SA t½to nearly normal. Because the elimination of SA is impaired in patients undergoing dialysis, the interdialytic SSA dosage should be reduced. Hemodialysis improves SA kinetics and may be followed by a normal SSA replacement dose. However, periodic monitoring of plasma SA levels is recommended when SSA dosing is begun in patients receiving dialysis. Clinical Pharmacology and Therapeutics (1986) 39, 420–424; doi:

Original languageEnglish (US)
Pages (from-to)420-424
Number of pages5
JournalClinical Pharmacology & Therapeutics
Issue number4
StatePublished - Apr 1986

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis'. Together they form a unique fingerprint.

Cite this